The role of extended pelvic lymph-node dissection (ePLND) in prostate cancer has been revisited in light of evidence from studies on staging via prostate-specific membrane antigen positron emission tomography/computed tomography. It is difficult to predict which individuals might benefit from ePLND. Patients should be counselled about this uncertainty and the risks of ePLND-associated morbidity as part of the shared decision-making process.
European urology. 2025 Apr 07 [Epub ahead of print]
Matthew J Roberts, Giorgio Gandaglia, Daniela E Oprea-Lager, Johan Stranne, Philip Cornford, Derya Tilki, EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines Panel
Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia; UQ Centre for Clinical Research, University of Queensland, Brisbane, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia., Division of Oncology/Unit of Urology, Soldera Prostate Cancer Laboratory, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy., Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands., Department of Urology, Institute of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Urology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden., Department of Urology, Liverpool University Hospitals NHS Trust, Liverpool, UK., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Türkiye. Electronic address: .